Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$21.00M$21.00Mderived+18.2% vs Q4 2021 Net Income-$1.42M-$1.42MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$12,016,000+10.6% Operating Incomederived-$1,444,000N/M Operating Cash Flowderived-$328,000N/M Margins · derivedGross margin57.2%−4.0 pt vs Q4 2021
Operating margin-6.9%+23.1 pt vs Q4 2021
Net margin-6.8%+23.2 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 8, 2023 · 67 d after period end